Advertisement

Topics

Puma Biotech Presents Interim Results Of Phase Ib/II FB-10 Trial Of PB272 In Combination With Trastuzumab Emtansine (T-DM1) In HER2-Positive Metastatic Breast Cancer At The 2017 AACR Annual Meeting

20:00 EDT 2 Apr 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Puma Biotech Presents Interim Results Of Phase Ib/II FB-10 Trial Of PB272 In Combination With Trastuzumab Emtansine (T-DM1) In HER2-Positive Metastatic Breast Cancer At The 2017 AACR Annual Meeting

NEXT ARTICLE

More From BioPortfolio on "Puma Biotech Presents Interim Results Of Phase Ib/II FB-10 Trial Of PB272 In Combination With Trastuzumab Emtansine (T-DM1) In HER2-Positive Metastatic Breast Cancer At The 2017 AACR Annual Meeting"

Quick Search
Advertisement